跳至主要内容
临床试验/NCT00565240
NCT00565240已完成不适用

Mid-luteal Phase Synchronization of Ovarian Folliculogenesis in Women Protocol: WHIRL-07-2971

University of Saskatchewan1 个研究点 分布在 1 个国家目标入组 41 人开始时间: 2007年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
41
试验地点
1
主要终点
To evaluate differences in the mechanisms of atresia, initiation of a new synchronous follicular wave, interval to follicle wave emergence, interval to emergence of dominant follicle, interval to menstruation, and endometrial thickness/pattern.

研究概览

简要总结

We hypothesize that administration of an aromatase inhibitor (AI) and hormonal contraceptives (HC) in the mid-luteal phase of the menstrual cycle will result in atresia of the follicles in the extant wave and cause synchronous re-emergence of a new follicular wave. We anticipate that this will provide us with information to facilitate the development of a new method for ovarian synchronization; a safer, more effective ovulation induction therapy; a new method for emergency contraception; and a greater understanding of human folliculogenesis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • female volunteers of childbearing potential;
  • are first time users of OC or have discontinued OC at least 2 months prior to study entry;
  • age between 18 and 35 years old;
  • normal body mass index (18-30);
  • has signed consent form; and
  • is in good health as confirmed by medical history, physical examination

排除标准

  • a positive pregnancy test will automatically exclude the volunteer from participation in this study.
  • any contraindication for oral contraception use;
  • known hypersensitivity to Letrozole and co-administered medications;
  • irregular menstrual cycles;
  • ultrasonographic evidence of ovarian dysfunction, such as Polycystic Ovary Syndrome (PCOS);
  • history of pituitary tumor;
  • HIV, HBV, HCV infection;
  • vaginal infection;
  • abnormal ECG;
  • abnormal lab tests for blood profile, liver function and renal function;
  • uncontrolled diabetes and blood pressure;
  • pregnancy (suspected or diagnosed) or lactation;
  • history or suspicion of drug or alcohol abuse;
  • history of severe mental disorders;
  • participation in an investigational drug trial within the 30 days prior to selection;
  • exhibits a disorder that is a contraindication to steroid hormonal therapy, including, for example, the following conditions:
  • history of, or actual, thrombophlebitis or thromboembolic disorders.
  • history of, or actual, cerebrovascular disorders.
  • history of, or actual, myocardial infarction or coronary artery disease.
  • acute liver disease.
  • history of, or actual, benign or malignant liver tumors.
  • history of, or suspected, carcinoma of the breast.
  • known, or suspected, estrogen-dependent neoplasia.
  • undiagnosed abnormal vaginal bleeding.
  • any ocular lesion arising from ophthalmic vascular disease, such as partial or complete loss of vision or defect in visual field.

研究组 & 干预措施

Oral Contraceptive

Experimental

干预措施: Marvelon (Drug)

Contraceptive Ring

Experimental

干预措施: Nuvaring (Drug)

Aromatase Inhibitors

Experimental

干预措施: Letrozole (Drug)

结局指标

主要结局

To evaluate differences in the mechanisms of atresia, initiation of a new synchronous follicular wave, interval to follicle wave emergence, interval to emergence of dominant follicle, interval to menstruation, and endometrial thickness/pattern.

时间窗: 24-28 days

次要结局

  • To evaluate between treatment group differences in ultrasonographic image attributes of follicular structures that develop after administration of treatment.(ongoing)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验